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Valerie Jones, RN
Otterbein University, Westerville, Ohio
Introduction
According to the literature, coronary
heart disease (CHD) is responsible for
370,000 deaths annually in the United
States (Centers for Disease Control and
Prevention [CDC], 2015). A symptom
commonly associated with CHD is
angina (US Department of Health &
Human Services, National Institute of
Health, National Heart, Lung, and Blood
Institute [NIH], 2011).
An estimated 300,000 to 900,000
patients in the United States have
refractory angina pectoris (RAP), with
nearly 100,00 new cases diagnosed
yearly (Manchanda, Aggarwal,
Aggarwal, & Soran, 2011). Kones
describes refractory angina as
continued angina class III/IV, in the nonsurgical candidate, with objective
evidence of ischemia despite optimum
medical treatment (Kones, R., 2010).
Many medications are available for the
treatment of angina. Beta blockers,
calcium channel blockers, and
angiotensin-converting enzyme
inhibitors are often useful in the
reduction of angina pain. Angioplasty
and life changes such as smoking
cessation, weight loss, and stress
reduction are additional treatment
options for the patient suffering from
chronic angina (Mayo Clinic, 2015).
Despite endless treatment options,
chronic angina continues to pose
significant challenges to both patient
and medical professional.
The patient diagnosed with chronic
angina frequently suffers from anxiety,
fear, pain, and decreased quality of life.
According to the literature, a continual
challenge of modern cardiovascular
medicine is to discover new, effective
treatments for patients with refractory
angina pectoris, a clinical condition
characterized by severe angina despite
optimal medical therapy (Gennari,
Gambini, Bassetti, Capogrossi, &
Pompilio, 2014). Enhanced external
counterpulsation (EECP) is approved for
the management of refractory angina.
EECP has proven beneficial in the
decrease of anginal symptoms,
decreased nitroglycerin use, and
improvement of exercise tolerance
(Sharma, Ramsey, & Tak, 2013).

Pathophysiology

Case Presentation
A 62 year old female diagnosed with
refractory angina pectoris, presents with
long standing debilitating angina pain.
The patient’s ability to ambulate and
preform activities of daily living are
significantly affected. Daily routine tasks
such as walking, climbing stairs, or basic
housekeeping become impossible
without the patient experiencing chest
pain (Manchanda et al., 2011). Symptom
relief could not be achieved through
standard pharmacological interventions.
Over the course of several years all
treatment options were explored. In
addition to medication management,
the patient underwent two coronary
artery bypass graft surgeries, and
numerous extensive stent placements.
Despite continued efforts, the
debilitating pain and anxiety associated
with angina continued, affecting all
aspects of the patient’s life.
With all other treatment options
exhausted, enhanced external
counterpulsation (EECP) therapy was
recommended. The treatment was noninvasive, painless, and beneficial. After
one month of continued EECP treatment
new collateral veins were noted to
several areas of the heart. The patient
reported a decrease in angina
symptoms. Additionally, a reduction in
pharmalogical treatment was noted.

Conclusion

Angina pectoris is a clinical syndrome of precordial discomfort
or pressure due to transient myocardial ischemia without
infarction (Warnica, 2015). Plaque disruption, thrombosis,
vasoconstriction, and supply-demand mismatch are all
contributory factors related to unstable angina (Medscape,
2013). Angina pectoris occurs as a consequence of increased
cardiac workload, subsequently myocardial oxygen demand
exceeds the capability of the coronary arteries to supply an
acceptable volume of oxygenated blood. (Warnica, 2015).
Myocardial oxygen demand is primarily determined by heart
rate, systolic wall tension, and contractility, narrowing of a
coronary artery typically results in angina that occurs during
exertion and is relieved by rest (Warnica, 2015). Unstable
angina falls within the range of clinical presentations referred
to collectively as acute coronary syndromes (ACS), ranging from
ST-segment elevation myocardial infarction (STEMI) to nonSTEMI (Medscape, 2013). The patient experiencing ACS should
be diagnosed with refractory angina when there is no
detectable release of enzymes and biomarkers of myocardial
necrosis (Medscape, 2013).

Implications of nursing
care related to ECP
Signs & Symptoms
The NIH describes angina as chest pain and
discomfort that occurs if the heart muscle
does not get enough oxygen rich blood. The
pain associated with angina is often
described as squeezing or pressure in the
chest, the pain may radiate to the jaw,
shoulders, arms, and neck (NIH, 2011). Signs
and symptoms associated with refractory
angina may vary significantly among
patients.
The patient may present with nausea,
lethargy, increased shortness of breath,
diaphoresis, dizziness, and generalized
weakness. Women experience angina
differently, typically presenting with jaw,
neck, throat, abdominal or back discomfort.
Diabetics may complain of increased
shortness of breath, in the absence of pain
(PubMed Health, 2010).

Significance of Pathophysiology
The nurse should be familiar with the pathological process that
occurs in the patient suffering from refractory angina. Becoming
familiar with the signs and symptoms associated with the disorder
will enable the nurse to provide accurate and timely care.
The advanced practice nurse must understand that the patient
may present with symptoms that are often mistaken for a MI. The
nurse must be familiar with cardiac enzyme testing. With proper
knowledge, the nurse can distinguish angina from a MI. Knowledge
of lab values is significant, as cardiac enzymes will be negative in
the patient with refractory angina.

In June 2002, the United States Food and Drug
Administration (FDA) approved enhanced external
counterpulsation (EECP), as an effective treatment for the
management of refractory angina (Sharma et al., 2013).
EECP is a non-invasive treatment in the frequency
reduction and intensity of angina episodes. During EECP
three pairs of pneumatic cuffs are applied to the lower
extremities at the levels of the calves and lower and upper
thighs, cuff inflation and deflation are synchronized with
the ECG (Kones, R., 2010). Typically, the patient will receive
thirty five ½ hour sessions over the course of 7 weeks.
(Kones, R., 2010).
EECP treatment requires three sets of pneumatic cuffs that
sequentially contract during diastole, and automatically
deflate before onset of systole (Kones, R., 2010). This
process increases aortic diastolic pressure, while enhancing
coronary blood flow and central venous return (Sharma et
al., 2013). Simply speaking, EECP increases the volume of
blood returning to the heart, which helps supply more
oxygen to its starved areas, therefore reducing angina
(Medscape, 2013).
According to the literature, EECP is an effective,
noninvasive, alternative treatment in the patient suffering
from refractory angina. Benefits of EECP are improved
ventricular function, systolic BP, coronary perfusion,
myocardial oxygen balance, and exercise tolerance.
Successful treatment decreases episodes of angina, sparing
nitrate use in an impressive proportion of patients (Kones,
R., 2010).
Additionally, EECP is also beneficial in the treatment of
stable congestive heart failure (CHF) (Sharma et al., 2013).
Researchers assume that cardiac benefits associated with
EECP are mediated though vascular endothelial growth
factor (VEGF) and nitric oxide mediated vasodilatation and
angiogenesis (Sharma et al., 2013).

According to the data, the number of
patients diagnosed yearly with
refractory angina continues to increase.
Pain reduction in this patient population
is a significant issue faced by clinicians.
EECP is an effective, noninvasive
treatment option for the patient
suffering from refractory angina
pectoris. Studies show that patients
treated with EECP have a 25% reduction
in angina symptoms weekly. According
to Kohn, 41% of patients treated with
EECP reported being pain free for 2
years post treatment (Kohn, 2010).
The advanced practice nurse, must
become familiar with all treatment
options available to the patient suffering
from angina. EECP should be considered
as part of the patient’s treatment plan,
when pharmalogical and surgical options
have been exhausted. Further education
to both clinician and patient is needed
with regard to this effective treatment
for refractory angina.
Many medical professionals are
unfamiliar with EECP therapy, therefore
EECP is underutilized in the treatment of
chronic angina. Increased provider
knowledge related to EECP may provide
a successful treatment option for the
patient suffering from chronic angina.
Research shows, EECP has been safely
used in the treatment of angina for the
past two decades, more recently, several
publications support its efficacy (Sharma
et al., 2013).
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